沃森生物：呼吸道合胞病毒mRNA疫苗临床研究申请获得受理 目前国内尚无该疫苗批准上市

Core Viewpoint - Watson Bio has applied for clinical trials of its respiratory syncytial virus mRNA vaccine, developed in collaboration with Fudan University and Shanghai Blue Magpie Biopharmaceutical Co., Ltd, which has been accepted by the National Medical Products Administration [1] Group 1 - The mRNA vaccine is based on an independently developed "mRNA vaccine technology platform" aimed at preventing lower respiratory tract diseases caused by respiratory syncytial virus infections [1] - Currently, there are no approved vaccines for this indication in China, while three have been approved abroad [1] - The acceptance of the clinical trial application will require further approval before clinical trials can commence, and it is not expected to have a significant impact on the company's operating performance for the current year [1]